Direct-to-consumer prescription drug advertising increased from $1.3 billion to $6 billion over the past 20 years, particularly for high-cost biologics and cancer immunotherapies.
Specialty Pharmacy
Advertisement
Moderate physical activity may improve progression-free survival and reduce treatment-related adverse effects in patients undergoing chemotherapy for advanced colorectal cancer.
Advertisement
Top news of the week from Specialty Pharmacy Times.
Top news of the day from across the health care landscape.
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.
Combination of ibrutinib and rituximab found to improve overall survival in patients with chronic lymphocytic leukemia.
Advertisement
Zanubrutinib, a Bruton’s tyrosine kinase inhibitor, is being evaluated in a broad pivotal clinical program across multiple B-cell malignancies.
Top news of the day from across the health care landscape.
A recent study demonstrates the clinical benefit from the use of direct-acting antivirals for hepatitis C virus in patients with a history of liver cancer.
Top news of the day from across the health care landscape.
Advertisement
Novel process may identify cancer metastasis at an earlier stage when it may be easier to treat.
Cancers of the lung, breast, prostate, and colon are most common in adults aged 85 years and older.
Research highlights the importance of regular blood testing to impove earlier detection of multiple myeloma.
Top news of the day from across the health care landscape.
Doug Long, vice president of Industry Relations at IQVIA, discusses rebate reform surrounding Medicare Part D and Part B in an interview with Specialty Pharmacy Times.
A phase 3 study evaluated the safety and efficacy of oral paclitaxel versus intravenous paclitaxel monotherapy in patients with metastatic breast cancer.
Aspirin therapy found to improve liver function test results and survival after transarterial embolization for hepatocellular carcinoma.
Top news of the day from across the health care landscape.
Study recommends similar clinical thresholds for diagnosing and managing giant cell arteritis for patients of different ethnicities.
Upadacitinib (Rinvoq, AbbVie) is indicated for adults with moderate-to-severe rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.
A phase 4 head-to-head trial compared ixekizumab (Taltz) with guselkumab (Tremfya) in patients with moderate-to-severe plaque psoriasis.
Top news of the day from across the health care landscape.
Top news of the week from Specialty Pharmacy Times.
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.
The approval of fedratinib (Inrebic, Celgene) provides another treatment option for patients with myelofibrosis, a rare bone marrow disorder.
Officials with the FDA have granted approval to entrectinib (Rozlytrek, Genentech) for 2 different cancer indications.
Top news of the day from across the health care landscape.
HIV-related immunosuppression may contribute to an elevated risk of cancer-related morbidity in elderly patients with the disease.
If approved, acalabrutinib (Calquence, AstraZeneca) will offer a chemotherapy-free treatment option for adults with chronic lymphocytic leukemia.
An analysis of a quality improvement project at an oncology specialty pharmacy showed that pharmacist interventions can reduce financial toxicity for patients.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Study: Many Patients Switching Biologics Because of Perceived Lack of Efficacy Treating Asthma
2
ADCs in Breast Cancer: Shaping the Future of HER2– and TROP2-Targeted Therapy
3
FDA Approves Targeted Combination Therapy for BRCA2-Mutated Prostate Cancer
4
Targeted ADCs Break Through Barriers in HER2-Positive Breast Cancer
5
